Valiant Laboratories Limited (BOM:543998)
India · Delayed Price · Currency is INR 121.40
-3.55 (-2.84%)
At close: Oct 7, 2026
Valiant Laboratories Revenue
Valiant Laboratories had revenue of 1.15B INR in the quarter ending June 30, 2026, with 146.22% growth. This brings the company's revenue in the last twelve months to 3.06B, up 89.64% year-over-year. In the fiscal year ending March 31, 2026, Valiant Laboratories had annual revenue of 2.37B with 78.04% growth.
Revenue (ttm)
3.06B
Revenue Growth
+89.64%
P/S Ratio
2.21
Revenue / Employee
36.42M
Employees
84
Market Cap
6.56B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.37B | 1.04B | 78.04% |
| Mar 31, 2025 | 1.33B | -486.75M | -26.74% |
| Mar 31, 2024 | 1.82B | -1.52B | -45.48% |
| Mar 31, 2023 | 3.34B | 215.43M | 6.90% |
| Mar 31, 2022 | 3.12B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anuh Pharma | 7.79B |
| Sudarshan Pharma Industries | 7.32B |
| Lincoln Pharmaceuticals | 6.94B |
| Wanbury | 6.53B |
| ZIM Laboratories | 3.97B |
| Albert David | 3.64B |
| Bharat Parenterals | 3.23B |
| Kilitch Drugs (India) | 2.37B |